Coordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC
Authors:
Open Access
Abstract
Background: Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma (ESCC); however, the underlying mechanisms and associated biomarkers that determine treatment response remain unclear. Objective: We delineate the mechanisms underlying the response and resistance, and elucidate the immune features that enhance neoadjuvant PD-L1 blockade efficacy in ESCC. Design: Here, we characterise the cellular dynamics following neoadjuvant PD-L1 blockade via analysing the single-cell transcriptomes of 210 978 cells and spatial transcriptomes of 20 tissue sections. Results: We identify coordinated cellular programmes centred on CXCL13 + CD8 + exhausted T cells, TNFRSF9 + CD4 + regulatory T cells, atypical memory B cells and APOE + macrophages, which coordinate the responses to neoadjuvant PD-L1 blockade at baseline. In post-treatment non-responder ESCCs, the cellular programmes exhibit an immunosuppressive phenotype, leading to the failure of therapeutic benefits. Furthermore, we reveal that lymphocyte activation gene 3 serves as a potential target and can potentiate the response via perturbation of the coordinated cellular programmes. Conclusions: Overall, our findings unravel the coordinated cellular programmes associated with treatment response, providing insights for prioritising individualised immunotherapy strategies in ESCC. Trial registration number: ChiCTR2400083452.Keywords
Funding Information
- National Natural Science Foundation of China (32322020)
- National Natural Science Foundation of China (32570796)
- National Natural Science Foundation of China (32571671)
- National Natural Science Foundation of China (92574205)
- National Natural Science Foundation of China (T2325009)
- Natural Science Foundation of Heilongjiang Province (JQ2025C005)
- National Key Research and Development Program of China (2024YFF1206602)
This publication has 46 references indexed in Scilit:
- Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapiesCancer Cell, 2025
- Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunityCell, 2024
- Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacyCancer Cell, 2024
- Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor TherapyAdvanced Science, 2024
- Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinomaCancer Cell, 2023
- Epithelial cells activate fibroblasts to promote esophageal cancer developmentCancer Cell, 2023
- Quiescent cancer cells resist T cell attack by forming an immunosuppressive nicheCell, 2022
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialCancer Cell, 2022
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA, 2021
- Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cellsJournal of Cellular Biochemistry, 2012